Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
about
New Pharmacotherapies in Chronic Lymphocytic Leukemia.The use of ofatumumab in the treatment of B-cell malignancies.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemiaRecent therapeutic advances in chronic lymphocytic leukemia.Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
P2860
Q37605306-F22CD68F-AD2D-4C1A-B1C4-3649D2A9524AQ38603992-B4D211F0-1542-4475-B6BB-057952820E30Q38818283-9E2A5899-8BC3-497F-AD22-93911F9714F1Q39227773-AC3F79DB-BB38-49EA-B16A-5EC3D5F01346Q46318389-EABC45E3-ECA0-4BCD-B422-E6A4A0A4DA6EQ47623717-599BC79B-714D-4BE0-A37E-AFA560063204Q50166015-0CB20592-3BEE-4F18-BAFD-8B70E5BE90DB
P2860
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Ofatumumab plus fludarabine an ...... s from the COMPLEMENT 2 trial.
@en
type
label
Ofatumumab plus fludarabine an ...... s from the COMPLEMENT 2 trial.
@en
prefLabel
Ofatumumab plus fludarabine an ...... s from the COMPLEMENT 2 trial.
@en
P2093
P2860
P1433
P1476
Ofatumumab plus fludarabine an ...... ts from the COMPLEMENT 2 trial
@en
P2093
Astrid McKeown
Chai-Ni Chang
Grygoriy Rekhtman
Ira V Gupta
Iryna Kryachok
Janusz Kłoczko
Javier Loscertales
Jerzy Z Błoński
Jodi L Carey
K Govind Babu
P2860
P304
P356
10.1080/10428194.2016.1233536
P577
2016-10-12T00:00:00Z